Hepwin Infusion, containing L-Ornithine L-Aspartate 5gm per vial, is a sterile intravenous preparation indicated for the management of hepatic encephalopathy and other liver-related metabolic disorders. L-Ornithine L-Aspartate is a hepatoprotective agent that facilitates ammonia detoxification by enhancing the urea cycle and glutamine synthesis in the liver and muscles, thereby reducing elevated blood ammonia levels commonly observed in patients with liver cirrhosis and acute liver failure. The infusion is administered under medical supervision, typically diluted and infused over a designated period to optimize therapeutic efficacy and minimize adverse effects. Hepwin Infusion is particularly beneficial in improving neuropsychiatric symptoms associated with hepatic encephalopathy, such as confusion, altered consciousness, and cognitive impairment, by lowering systemic ammonia concentrations. It is also used adjunctively in chronic liver diseases to support liver function and metabolic balance. Contraindications include hypersensitivity to the active ingredient or excipients. Caution is advised in patients with renal impairment or electrolyte imbalances. Common adverse reactions are generally mild and may include local infusion site reactions or transient gastrointestinal disturbances. Hepwin Infusion should be used as part of a comprehensive treatment plan, including dietary management and other supportive measures, under the guidance of a healthcare professional.